What is Black Diamond Therapeutics, Inc.'s earnings per share (EPS)?

Black Diamond Therapeutics, Inc. (BDTX) reported diluted earnings per share of $0.39 for fiscal year 2025. This represents a 130.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Black Diamond Therapeutics, Inc. Financials

BDTX

FY2025 annual

Revenue $70.0M YoY not available

Net Income Not reported for FY2025

EPS (Diluted) $0.39 +130.7% YoY

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Black Diamond Therapeutics, Inc. (BDTX) reported $70.0M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BDTX FY2025 2026-08-29

The dominant mechanic is a shift from development losses to operating profitability, while investment still outruns internally generated cash.

In FY2025, operating cash flow of $29.6M was more than twice operating income of $12.5M, indicating cash conversion stronger than the reported profit line. Because depreciation was only $325K, the gap points chiefly to working-capital or other operating adjustments rather than asset depreciation.

FY2023's operating loss was -$86.5M; by FY2025, operating margin reached 17.9%. With FY2025 revenue at $70M, the transition reflects a new operating phase, but the available lines cannot distinguish pricing, mix, or cost effects.

Debt-to-equity fell to 0.3x in FY2025 from 0.4x in FY2023, indicating less reliance on liabilities relative to equity. The current ratio reached 8.4x, while investing outflows exceeded operating cash flow, so near-neutral financing implies use of existing resources.

Financial Health Signals

Financial Health Score 53/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Black Diamond Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Black Diamond Therapeutics, Inc. has an operating margin of 17.9%, meaning the company retains $18 of operating profit per $100 of revenue. This strong profitability earns a score of 85/100, reflecting efficient cost management and pricing power.

Growth

Not available for Black Diamond Therapeutics, Inc., and counted as zero in the overall score.

Leverage

Black Diamond Therapeutics, Inc. carries a low D/E ratio of 0.27, meaning only $0.27 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 70/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 8.42, Black Diamond Therapeutics, Inc. holds $8.42 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 96/100.

Cash Flow

Not available for Black Diamond Therapeutics, Inc., and counted as zero in the overall score.

Returns

Altman Z-Score Distress

-0.44

Black Diamond Therapeutics, Inc. scores -0.44, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($120.7M) relative to total liabilities ($30.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$70.0M

Black Diamond Therapeutics, Inc. generated $70.0M in revenue in fiscal year 2025.

EBITDA

$12.8M

YoY+116.4%

Black Diamond Therapeutics, Inc.'s EBITDA was $12.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 116.4% from the prior year.

EPS (Diluted)

$0.39

YoY+130.7%

Black Diamond Therapeutics, Inc. earned $0.39 per diluted share (EPS) in fiscal year 2025. This represents an increase of 130.7% from the prior year.

Net Income

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$21.0M

YoY-42.4%

5Y CAGR-9.5%

Black Diamond Therapeutics, Inc. held $21.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

57M

YoY+1.1%

5Y CAGR+9.7%

Black Diamond Therapeutics, Inc. had 57M shares outstanding in fiscal year 2025. This represents an increase of 1.1% from the prior year.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Operating Margin

17.9%

Black Diamond Therapeutics, Inc.'s operating margin was 17.9% in fiscal year 2025, reflecting core business profitability.

Gross Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$33.6M

YoY-34.6%

5Y CAGR-7.0%

Black Diamond Therapeutics, Inc. invested $33.6M in research and development in fiscal year 2025. This represents a decrease of 34.6% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

BDTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BDTX quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Revenue	N/A	$70.0M	$0	N/A	N/A	N/A	$0	$0	$0
R&D Expenses	N/A	$33.6M-34.6%	$51.3M-13.5%	$59.4M-7.9%	$64.4M-33.5%	$96.8M+100.9%	$48.2M+121.6%	$21.8M+213.0%	$7.0M
SG&A Expenses	N/A	$16.6M-39.7%	$27.5M+1.3%	$27.1M-4.5%	$28.4M-5.5%	$30.0M+40.6%	$21.4M+181.8%	$7.6M+287.9%	$2.0M
Operating Income	N/A	$12.5M+115.9%	-$78.8M+8.9%	-$86.5M+6.9%	-$92.8M+26.8%	-$126.9M-82.4%	-$69.6M-137.2%	-$29.3M-229.4%	-$8.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$1K	$0	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	N/A	N/A	-$82.4M+9.6%	-$91.2M+27.4%	-$125.6M-86.7%	-$67.3M-90.7%	-$35.3M-294.8%	-$8.9M
EPS (Diluted)	-$0.74	$0.39+130.7%	-$1.27+32.4%	-$1.88+25.4%	-$2.52+27.4%	-$3.47-69.3%	-$2.05	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	$0	N/A	$0	$0-100.0%	$70.0M	N/A	$0
R&D Expenses	$7.4M+5.6%	$7.0M	N/A	$7.4M-20.2%	$9.3M-11.3%	$10.5M	N/A	$12.9M
SG&A Expenses	$4.7M+9.6%	$4.3M	N/A	$3.5M-13.7%	$4.1M-17.4%	$5.0M	N/A	$5.2M
Operating Income	-$12.1M-7.1%	-$11.3M	N/A	-$11.0M+18.2%	-$13.4M-124.6%	$54.5M	N/A	-$18.1M
Income Tax	N/A	N/A	N/A	N/A	N/A	$226K	N/A	N/A
Net Income	-$9.9M-9.6%	-$9.0M	N/A	-$8.5M+19.5%	-$10.6M-118.7%	$56.5M	N/A	-$15.6M
EPS (Diluted)	-$0.17-6.3%	-$0.16+38.5%	-$0.26-73.3%	-$0.15+21.1%	-$0.19-119.4%	$0.98+450.0%	-$0.280.0%	-$0.28

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

BDTX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BDTX quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Total Assets	$143.0M+16.6%	$122.6M-22.7%	$158.6M+1.5%	$156.3M-36.9%	$247.7M-24.9%	$329.7M+108.3%	$158.3M+205.4%	$51.8M
Current Assets	$132.4M+30.9%	$101.2M-24.5%	$134.0M+5.0%	$127.7M-40.8%	$215.7M-32.5%	$319.6M+105.2%	$155.7M+201.3%	$51.7M
Cash & Equivalents	$21.0M-42.4%	$36.4M-35.2%	$56.2M+63.8%	$34.3M-47.8%	$65.8M+90.1%	$34.6M-77.6%	$154.7M+199.4%	$51.7M
Total Liabilities	$30.8M-21.7%	$39.4M-5.9%	$41.8M+3.1%	$40.6M-21.7%	$51.8M+136.3%	$21.9M-89.3%	$205.5M+205.0%	$67.4M
Current Liabilities	$15.7M-23.5%	$20.6M+4.7%	$19.6M+28.7%	$15.3M-35.4%	$23.6M+66.3%	$14.2M+192.4%	$4.9M+88.9%	$2.6M
Total Equity	$112.2M+34.7%	$83.3M-28.7%	$116.7M+0.9%	$115.7M-40.9%	$195.9M-36.3%	$307.8M+752.6%	-$47.2M-203.4%	-$15.5M
Retained Earnings	-$464.7M+4.6%	-$487.1M-16.7%	-$417.4M-24.6%	-$335.0M-37.4%	-$243.8M-106.2%	-$118.2M-131.9%	-$51.0M-224.4%	-$15.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$125.0M-5.9%	$132.9M-7.1%	$143.0M-9.3%	$157.7M-5.2%	$166.4M-5.6%	$176.2M+43.7%	$122.6M-11.1%	$137.9M
Current Assets	$115.4M-6.2%	$123.0M-7.2%	$132.4M-4.7%	$139.0M-5.3%	$146.7M-5.8%	$155.7M+53.9%	$101.2M-12.4%	$115.5M
Cash & Equivalents	$19.2M-36.2%	$30.1M+43.3%	$21.0M-32.0%	$30.9M+2.9%	$30.0M-69.5%	$98.4M+170.1%	$36.4M+55.5%	$23.4M
Total Liabilities	$28.9M+1.1%	$28.6M-7.1%	$30.8M-2.5%	$31.6M-6.5%	$33.8M-2.7%	$34.7M-11.8%	$39.4M-2.8%	$40.5M
Current Liabilities	$15.8M+9.0%	$14.5M-7.6%	$15.7M+1.2%	$15.5M-7.5%	$16.8M-0.2%	$16.8M-18.1%	$20.6M-1.1%	$20.8M
Total Equity	$96.1M-7.9%	$104.3M-7.1%	$112.2M-11.1%	$126.2M-4.9%	$132.6M-6.3%	$141.5M+69.9%	$83.3M-14.5%	$97.4M
Retained Earnings	-$483.7M-2.1%	-$473.8M-1.9%	-$464.7M-3.4%	-$449.6M-1.9%	-$441.1M-2.5%	-$430.6M+11.6%	-$487.1M-3.4%	-$471.1M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

BDTX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BDTX quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Operating Cash Flow	-$32.8M	$29.6M+147.5%	-$62.3M+6.6%	-$66.7M+21.6%	-$85.1M+15.0%	-$100.1M-92.1%	-$52.1M-111.3%	-$24.7M-191.9%	-$8.5M
Capital Expenditures	N/A	N/A	$0-100.0%	$33K-82.8%	$192K-92.9%	$2.7M+1808.5%	$142K+576.2%	$21K-72.4%	$76K
Free Cash Flow	N/A	N/A	-$62.3M+6.7%	-$66.8M+21.7%	-$85.3M+17.1%	-$102.9M-96.7%	-$52.3M-111.7%	-$24.7M-189.5%	-$8.5M
Investing Cash Flow	$22.1M	-$44.9M-364.6%	$17.0M+3.8%	$16.3M-69.4%	$53.4M-59.1%	$130.6M+146.4%	-$281.7M-1341285.7%	-$21K+72.4%	-$76K
Financing Cash Flow	-$30K	-$146K-100.6%	$25.5M-64.5%	$71.9M+40539.5%	$177K-75.7%	$729K-99.7%	$214.9M+68.2%	$127.8M+144.2%	$52.3M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$8.0M+22.1%	-$10.2M-50.8%	-$6.8M+13.5%	-$7.8M+14.3%	-$9.2M-117.1%	$53.4M+454.8%	-$15.1M-33.0%	-$11.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$15.1M	N/A
Investing Cash Flow	-$3.1M-116.0%	$19.5M+775.0%	-$2.9M-133.6%	$8.6M+114.5%	-$59.2M-792.1%	$8.5M-69.2%	$27.8M+1166.3%	$2.2M
Financing Cash Flow	$217K+217.3%	-$185K+5.6%	-$196K-246.3%	$134K+215.5%	-$116K-462.5%	$32K-89.0%	$291K+215.5%	-$252K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BDTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BDTX quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Operating Margin	17.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	-70.6%+8.2pp	-78.8%-14.7pp	-64.1%-42.3pp	-21.9%	N/A	N/A
Return on Assets	N/A	N/A	-52.0%+6.4pp	-58.4%-7.6pp	-50.7%-30.3pp	-20.4%+1.9pp	-22.3%-5.0pp	-17.2%
Current Ratio	8.42+3.5x	4.92-1.9x	6.82-1.5x	8.37-0.8x	9.12-13.4x	22.48-9.5x	32.02+11.9x	20.07
Debt-to-Equity	0.27-0.2x	0.47+0.1x	0.360.0x	0.35+0.1x	0.26+0.2x	0.07	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Margin	N/A	N/A	N/A	N/A	N/A	77.9%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	80.8%	N/A	N/A
Return on Equity	-10.3%-1.7pp	-8.7%	N/A	-6.7%+1.2pp	-8.0%-47.9pp	40.0%	N/A	-16.0%
Return on Assets	-7.9%-1.1pp	-6.8%	N/A	-5.4%+1.0pp	-6.3%-38.4pp	32.1%	N/A	-11.3%
Current Ratio	7.28-1.2x	8.460.0x	8.42-0.5x	8.94+0.2x	8.73-0.5x	9.24+4.3x	4.92-0.6x	5.55
Debt-to-Equity	0.300.0x	0.270.0x	0.270.0x	0.250.0x	0.250.0x	0.25-0.2x	0.47+0.1x	0.42

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Similar Companies

C4 Therapeutics, Inc. CCCC

$473.6M

Elicio Therapeutics, Inc. ELTX

$74.6M

NeOnc Technologies Holdings Inc NTHI

$121.6M

Kyverna Therapeutics KYTX

$517.6M

Nuvectis Pharma, Inc. NVCT

$774.6M

Where Black Diamond Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Black Diamond Therapeutics, Inc.'s annual revenue?

Black Diamond Therapeutics, Inc. (BDTX) reported $70.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

What is Black Diamond Therapeutics, Inc.'s EBITDA?

Black Diamond Therapeutics, Inc. (BDTX) had EBITDA of $12.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Black Diamond Therapeutics, Inc.'s operating margin?

Black Diamond Therapeutics, Inc. (BDTX) had an operating margin of 17.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Black Diamond Therapeutics, Inc.'s operating cash flow?

Black Diamond Therapeutics, Inc. (BDTX) generated $29.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Black Diamond Therapeutics, Inc.'s total assets?

Black Diamond Therapeutics, Inc. (BDTX) had $143.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Black Diamond Therapeutics, Inc. spend on research and development?

Black Diamond Therapeutics, Inc. (BDTX) invested $33.6M in research and development during fiscal year 2025.

How many shares does Black Diamond Therapeutics, Inc. have outstanding?

Black Diamond Therapeutics, Inc. (BDTX) had 57M shares outstanding as of fiscal year 2025.

What is Black Diamond Therapeutics, Inc.'s current ratio?

Black Diamond Therapeutics, Inc. (BDTX) had a current ratio of 8.42 as of fiscal year 2025, which is generally considered healthy.

What is Black Diamond Therapeutics, Inc.'s debt-to-equity ratio?

Black Diamond Therapeutics, Inc. (BDTX) had a debt-to-equity ratio of 0.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Black Diamond Therapeutics, Inc.'s Altman Z-Score?

Black Diamond Therapeutics, Inc. (BDTX) has an Altman Z-Score of -0.44, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

How financially healthy is Black Diamond Therapeutics, Inc.?

Black Diamond Therapeutics, Inc. (BDTX) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.